查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403342

2030 年治疗诊断学市场预测：按疾病类型、技术、最终用户和地区进行的全球分析

Theranostics Market Forecasts to 2030 - Global Analysis By Disease Type (Neurological Disorder, Immunological Disorder, Cardiovascular Disease, Oncology and Other Disease Types), Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球治疗诊断学市场规模为 7 亿美元，预计到 2030 年将达到 17 亿美元，预测期内复合年增长率为 11.8%。

一个名为「治疗诊断学」的新医学领域将治疗方法和诊断结合成一个紧密结合的程序。 “治疗诊断学”结合了“治疗”和“诊断”，强调如何整合患者护理的两个方面。它力求根据每位患者的独特特征和疾病概况提供精确、个体化的治疗计划。治疗诊断学领域使用先进的诊断方法，如分子成像、基因检测、生物标记分析和分子谱分析。

诊断技术的进步

分子影像、次世代定序(NGS) 等先进诊断技术以及正子断层扫描 (PET) 和磁振造影(MRI) 等高解析度显像模式正在提高疾病诊断的准确性和灵敏度。这种精确度使得能够识别与疾病相关的特定生物标记、基因突变和分子标靶，这对于开发定製药物的治疗诊断学至关重要。此外，治疗诊断学领域的早期识别允许快速介入和客製化治疗计划，透过允许更密集和强化的治疗有可能改善患者的治疗结果。

关于治疗诊断学测试缺乏足够的监管

在缺乏精确、明确的立法的情况下，治疗诊断学测试的许可程序、验证规范和品质标准都可能不清楚。这种不可预测性阻碍了新诊断方法的创建和使用，并可能延迟突破性药物的上市。不确定的法律规范和不同的国际要求可能会延迟治疗诊断测试向市场的推出。公司可能难以通过复杂的监管程序，这可能导致核准等待时间更长并阻碍市场成长。

加大倡议力度

研究和开发资金支持尖端诊断设备和技术的创建。这些进展将提高诊断测试的敏感性、特异性和准确性，从而能够更精确地识别疾病生物标记、基因突变和分子标靶。治疗诊断学在很大程度上依赖改进的诊断方法来指导客製化的治疗计划。治疗诊断学产品和服务的扩展和商业化是由研发成果的市场成功推动的，为患者和医疗保健专业人员提供更个体化和高效的治疗方法。

监管挑战

新的治疗诊断测试和产品的推出可能会因严格的监管要求、复杂的核准程序和漫长的监管核准流程而被推迟。这可能使患者难以按时接受个人化医疗和最尖端科技。由于核准程序和监管要求因地区而异，因此可能会出现市场碎片化。不同地理位置的监管要求不一致可能会导致治疗诊断测试的取得机会不平等，进而导致这些测试的可用性和采用率存在差异。

COVID-19 的影响

这次疫情爆发凸显了快速、准确的诊断检测的重要性。为了识别 SARS-CoV-2，PCR 和基于核酸扩增的检测等分子诊断方法的使用急剧增加。对分子诊断方法的关注凸显了类似方法在治疗治疗诊断学治疗的其他疾病中的重要性。远端医疗和远端监控技术越来越受到青睐，以最大限度地减少亲自就诊并保持护理的连续性。这项变更可能会影响治疗诊断学策略的实施方式，包括远端监控和诊断。

预计神经系统疾病领域在预测期内将是最大的。

神经系统疾病领域预计将出现良好的成长，因为涉及大脑、脊髓和周围神经的多种疾病被称为神经系统疾病。这些疾病包括多发性硬化症、癫痫、帕金森氏症、阿兹海默症和各种神经病变。此外，治疗诊断学利用基因分析、分子生物标记和先进的影像方式来促进神经系统疾病的早期和准确识别。因此，准确的诊断仪器透过检测与这些病理相关的特定生物标记和病理变化来支持疾病追踪和预后。

聚合酶炼式反应 (PCR) 领域预计在预测期内复合年增长率最高

聚合酶链反应（PCR）领域预计在预测期内将以最高复合年增长率成长，特别是聚合酶链反应（PCR）对于诊断和预后应用至关重要。治疗诊断学使用分子生物学技术聚合酶炼式反应 (PCR) 来识别和扩增特定的 DNA 或 RNA 序列。 PCR是发现感染疾病、基因突变以及与各种疾病相关的生物标记的重要工具。基于 PCR 的补充诊断技术可以预测患者对特定治疗的反应。因此，透过采用PCR分析特定的基因突变和生物标记物，医疗保健专业人员可以为每位患者选择最合适的治疗策略，并最大限度地提高治疗效果。

比最大的地区

预计北美在预测期内将占据最大的市场占有率。这是因为随着北美越来越多的人患有癌症，对更有效和客製化的治疗方法方案的需求日益增长。治疗诊断学可以透过提供基于特定生物标记的标靶药物来帮助更准确的癌症诊断和治疗。此外，个人化医疗技术正变得越来越普及。因此，我们的目标是根据每位患者的基因组成、疾病特征和生物标记来量身定制治疗方法，从而推动市场成长。

复合年增长率最高的地区：

预计欧洲在预测期内的复合年增长率最高。这是因为癌症和其他慢性疾病的盛行率不断上升，推动了对更个体化和有效治疗方法的需求。治疗诊断学有望透过根据特定生物标记提供定製药物来改善患者的治疗效果而受到关注。在亚太地区，正在进行大量投资来加强医疗保健基础设施，包括个人化医疗、分子诊断和先进成像技术计划。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球治疗诊断学市场：依疾病类型

  • 神经病变
  • 免疫疾病
  • 循环系统疾病
  • 肿瘤学
    • 大肠直肠癌
    • 乳癌
    • 子宫颈癌
    • 肺癌
  • 其他疾病类型

第六章全球治疗诊断学市场：依技术分类

  • 原位杂合反应
  • 聚合酶炼式反应 (PCR)
  • 免疫组织化学
  • 顺序
  • 其他技术

第七章全球治疗诊断学市场：依最终使用者分类

  • 诊断实验室
  • 医院和诊所
  • 其他最终用户

第八章全球治疗诊断学市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Beckman Coulter, Inc.
  • QIAGEN
  • Abbott Laboratories
  • Myriad Genetics, Inc.
  • Foundation Medicine, Inc.
  • AmeriPath, Inc.
  • Focus Diagnostics
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Leica Biosystems Nussloch GmBH
  • GE Healthcare
  • Pfizer, Inc.
Product Code: SMRC24567

According to Stratistics MRC, the Global Theranostics Market is accounted for $0.7 billion in 2023 and is expected to reach $1.7 billion by 2030 growing at a CAGR of 11.8% during the forecast period. A new area of medicine called "theranostics" blends therapeutic and diagnostic methods into a single, cohesive procedure. Combining the terms "therapy" and "diagnostics," "theranostics" emphasizes how both aspects of patient treatment should be integrated. It seeks to offer accurate and individualized treatment plans based on the unique traits and illness profiles of each patient. Advanced diagnostic methods such as molecular imaging, genetic testing, biomarker analysis, and molecular profiling are used in the field of theranostics.

Market Dynamics:

Driver:

Advancements in diagnostic technologies

The accuracy and sensitivity of illness diagnosis have been improved by sophisticated diagnostic technologies, such as molecular imaging, next-generation sequencing (NGS), and high-resolution imaging modalities including positron emission tomography (PET) and magnetic resonance imaging (MRI). The ability to identify certain biomarkers, genetic variants, or molecular targets linked to illnesses is made possible by this precision, and this is essential in theranostics for the development of tailored medicines. Moreover, early identification in the field of theranostics allows for prompt intervention and customized treatment plans, which may enhance patient outcomes by enabling more powerful and focused therapy.

Restraint:

Lack of properly defined regulations for theranostics tests

The clearance procedure, validation specifications, and quality criteria for theranostic testing might all be unclear in the absence of precise and defined laws. This unpredictability may impede the creation and use of novel diagnostics, delaying the release of ground-breaking theranostic products. Theranostic test market introduction may be delayed by unclear regulatory frameworks and disparate international requirements. Businesses may have trouble navigating complicated regulatory procedures, which might lead to longer wait times for clearances impeding the market growth.

Opportunity:

Increasing research and development initiatives

R&D expenditures support the creation of cutting-edge diagnostic instruments and technology. These developments improve diagnostic test sensitivity, specificity, and accuracy, making it possible to identify disease biomarkers, genetic variants, and molecular targets more accurately. Theranostics relies heavily on improved diagnostics to direct customized treatment plans. The expansion and commercialization of theranostic goods and services are facilitated by successful R&D outcomes on the market giving patients and healthcare professionals access to more individualized and efficient treatment alternatives.

Threat:

Regulatory challenges

New theranostic test and product launches might be delayed by onerous regulatory requirements, convoluted approval procedures, and protracted regulatory approval processes. This hold-up may make it more difficult for patients to receive individualized care and cutting-edge technologies on schedule. Market fragmentation may arise due to variations in approval procedures and regulatory requirements across different locations. Different geographic locations may experience unequal access to theranostic testing due to inconsistent regulatory requirements, which might lead to differences in the availability and uptake of these tests.

COVID-19 Impact

The epidemic brought to light how crucial quick and precise diagnostic testing is. The use of molecular diagnostic methods, such as PCR and assays based on nucleic acid amplification, has increased dramatically in order to identify SARS-CoV-2. The importance of comparable methods in treating other illnesses, such as those addressed by theranostics, has been highlighted by this focus on molecular diagnostics. In order to minimize in-person encounters and maintain continuity of treatment, telemedicine and remote monitoring technologies gained increasing traction. This change may affect how theranostics tactics that include remote monitoring and diagnostics are implemented.

The neurological disorder segment is expected to be the largest during the forecast period

The neurological disorder segment is estimated to have a lucrative growth, owing to a wide range of illnesses involving the brain, spinal cord, and peripheral nerves are referred to as neurological diseases. These illnesses include multiple sclerosis, epilepsy, Parkinson's disease, Alzheimer's disease, and different neuropathies. Moreover, theranostics makes use of genetic profiling, molecular biomarkers, and sophisticated imaging methods to facilitate the early and precise identification of neurological illnesses. Thus, accurate diagnostic instruments support illness tracking and prognosis by detecting certain biomarkers or pathological alterations linked to these conditions.

The polymerase chain reaction (PCR) segment is expected to have the highest CAGR during the forecast period

The polymerase chain reaction (PCR) segment is anticipated to witness the highest CAGR growth during the forecast period, as polymerase chain reaction (PCR) is essential, particularly for diagnostic and prognostic uses. Theranostics uses polymerase chain reaction (PCR), a molecular biology technique, to identify and amplify specific DNA or RNA sequences. PCR is a vital tool for finding infections, genetic variants, and biomarkers linked to a variety of disorders. Complementary diagnostic techniques based on PCR can forecast how a patient will react to specific treatments. Hence healthcare professionals may choose the best course of action for each patient by employing PCR to analyze certain genetic variants or biomarkers, which maximizes therapeutic outcomes.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the need for more efficient and customized treatment choices that have grown as cancer cases become increasingly common in North America. Theranostics helps with more accurate cancer diagnosis and therapy by providing targeted medicines based on certain biomarkers. Moreover, personalized medicine techniques are becoming more and more popular. Thus, the goal is to customize therapies for each patient according to their genetic composition, illness features, and biomarkers driving the growth of the market.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, as growing cancer and other chronic illness incidence has increased need for more individualized and efficient treatment alternatives. Theranostics attracted attention for its promise to enhance patient outcomes because of its capacity to provide tailored medicines based on certain biomarkers. The Asia Pacific area has seen significant investments in enhancing its healthcare infrastructure, encompassing projects in personalized medicine, molecular diagnostics, and sophisticated imaging technology.

Key players in the market:

Some of the key players profiled in the Theranostics Market include Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Beckman Coulter, Inc., QIAGEN, Abbott Laboratories, Myriad Genetics, Inc., Foundation Medicine, Inc., AmeriPath, Inc., Focus Diagnostics, Illumina, Inc., Agilent Technologies, Inc., Leica Biosystems Nussloch GmBH, GE Healthcare and Pfizer, Inc.

Key Developments:

In November 2023, Roche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List. The tests complete Roche's panel used for the differential diagnosis of acute viral hepatitis caused by the hepatitis A, B, C and E viruses.

In October 2023, Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics, and the transaction values Olink at approximately $3.1 billion which includes net cash of approximately $143 million.

In October 2023, Beckman Coulter Diagnostics, announced it acquired StoCastic, LLC. a leading artificial intelligence company that provides evidence-based decision support for hospital emergency departments (ED).

Disease Types Covered:

  • Neurological Disorder
  • Immunological Disorder
  • Cardiovascular Disease
  • Oncology
  • Other Disease Types

Technologies Covered:

  • In Situ Hybridization
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry
  • Sequencing
  • Other Technologies

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Theranostics Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Neurological Disorder
  • 5.3 Immunological Disorder
  • 5.4 Cardiovascular Disease
  • 5.5 Oncology
    • 5.5.1 Colorectal Cancer
    • 5.5.2 Breast Cancer
    • 5.5.3 Cervical Cancer
    • 5.5.4 Lung Cancer
  • 5.6 Other Disease Types

6 Global Theranostics Market, By Technology

  • 6.1 Introduction
  • 6.2 In Situ Hybridization
  • 6.3 Polymerase Chain Reaction (PCR)
  • 6.4 Immunohistochemistry
  • 6.5 Sequencing
  • 6.6 Other Technologies

7 Global Theranostics Market, By End User

  • 7.1 Introduction
  • 7.2 Diagnostic Laboratories
  • 7.3 Hospitals & Clinics
  • 7.4 Other End Users

8 Global Theranostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.8 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Hoffmann-La Roche Ltd
  • 10.2 Thermo Fisher Scientific Inc.
  • 10.3 Beckman Coulter, Inc.
  • 10.4 QIAGEN
  • 10.5 Abbott Laboratories
  • 10.6 Myriad Genetics, Inc.
  • 10.7 Foundation Medicine, Inc.
  • 10.8 AmeriPath, Inc.
  • 10.9 Focus Diagnostics
  • 10.10 Illumina, Inc.
  • 10.11 Agilent Technologies, Inc.
  • 10.12 Leica Biosystems Nussloch GmBH
  • 10.13 GE Healthcare
  • 10.14 Pfizer, Inc.

List of Tables

  • Table 1 Global Theranostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 3 Global Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 4 Global Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 5 Global Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 6 Global Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 7 Global Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 8 Global Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 9 Global Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 10 Global Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 11 Global Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 12 Global Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 13 Global Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 14 Global Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 15 Global Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 16 Global Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 17 Global Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 18 Global Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 19 Global Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 20 Global Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 21 Global Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 22 North America Theranostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 23 North America Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 24 North America Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 25 North America Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 26 North America Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 27 North America Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 28 North America Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 29 North America Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 30 North America Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 31 North America Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 32 North America Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 33 North America Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 34 North America Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 35 North America Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 36 North America Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 37 North America Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 38 North America Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 39 North America Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 40 North America Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 41 North America Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 42 North America Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 43 Europe Theranostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Europe Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 45 Europe Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 46 Europe Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 47 Europe Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 48 Europe Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 49 Europe Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 50 Europe Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 51 Europe Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 52 Europe Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 53 Europe Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 54 Europe Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 55 Europe Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 56 Europe Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 57 Europe Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 58 Europe Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 59 Europe Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 60 Europe Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 61 Europe Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 62 Europe Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 63 Europe Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 64 Asia Pacific Theranostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 65 Asia Pacific Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 66 Asia Pacific Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 67 Asia Pacific Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 68 Asia Pacific Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 69 Asia Pacific Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 70 Asia Pacific Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 71 Asia Pacific Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 72 Asia Pacific Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 73 Asia Pacific Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 74 Asia Pacific Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 75 Asia Pacific Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 76 Asia Pacific Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 77 Asia Pacific Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 78 Asia Pacific Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 79 Asia Pacific Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 80 Asia Pacific Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 81 Asia Pacific Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 82 Asia Pacific Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 83 Asia Pacific Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 84 Asia Pacific Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 85 South America Theranostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 86 South America Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 87 South America Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 88 South America Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 89 South America Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 90 South America Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 91 South America Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 92 South America Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 93 South America Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 94 South America Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 95 South America Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 96 South America Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 97 South America Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 98 South America Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 99 South America Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 100 South America Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 101 South America Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 102 South America Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 103 South America Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 104 South America Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 105 South America Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 106 Middle East & Africa Theranostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 107 Middle East & Africa Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 108 Middle East & Africa Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 109 Middle East & Africa Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 110 Middle East & Africa Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 111 Middle East & Africa Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 112 Middle East & Africa Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 113 Middle East & Africa Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 114 Middle East & Africa Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 115 Middle East & Africa Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 116 Middle East & Africa Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 117 Middle East & Africa Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 118 Middle East & Africa Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 119 Middle East & Africa Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 120 Middle East & Africa Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 121 Middle East & Africa Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 122 Middle East & Africa Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 123 Middle East & Africa Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 124 Middle East & Africa Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 125 Middle East & Africa Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 126 Middle East & Africa Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)